What is the equity of Karo Pharma this year?
Karo Pharma has equity of 5.81 B SEK this year.
Karo Pharma Equity 2024
Karo Pharma Equity
5.81 B SEK
Ticker
KARO.ST
ISIN
SE0007464888
WKN
A14YW4
In 2024, Karo Pharma's equity was 5.81 B SEK, a 0% increase from the 0 SEK equity in the previous year.
Karo Pharma Aktienanalyse
What does Karo Pharma do?
Karo Pharma AB is a Swedish pharmaceutical company specializing in the manufacturing and distribution of over-the-counter drugs and health products. The company's history dates back to 1986 when it was founded as Karo Bioforskning. Over time, the company went through several restructurings and realignments until it finally became an independent company listed on the Stockholm Stock Exchange in 2017 under the name Karo Pharma AB. Karo Pharma's business model is based on a broad portfolio of over-the-counter drugs and health products tailored to the needs of consumers in different countries and for different indications. The product range includes pain relievers, cold remedies, medications for digestive disorders, and eye care products. In addition, the company also offers dietary supplements and other health products. Karo Pharma operates in three main segments: Consumer Healthcare, Prescription Pharmaceuticals, and Out-licensing. Consumer Healthcare focuses on over-the-counter drugs and health products for end consumers. Examples include VagiVital, a medication for the treatment of vaginal yeast infections, and MolluscumVital, a product for the removal of warts. In the Prescription Pharmaceuticals segment, Karo Pharma offers prescription drugs for specific indications, such as Eklira, used in the treatment of chronic obstructive pulmonary disease (COPD). The Out-licensing segment involves the licensing of products and technologies to other companies. Karo Pharma has a particular focus on the development of products based on natural active ingredients. For example, Prenoxdiazin, used for pain relief, is based on an extract from the root of peonies. Natural ingredients are preferred in the development of other products as well, to maximize their compatibility and effectiveness. Overall, Karo Pharma's portfolio includes more than 20 brands and over 100 products distributed in various countries. The company is headquartered in Stockholm and operates in several European countries, as well as in the United States and Canada. Karo Pharma emphasizes close collaboration with doctors and pharmacists to ensure that its products meet the needs of consumers optimally. In recent years, Karo Pharma has become the leading provider of over-the-counter drugs and health products in Scandinavia and now plans to expand its presence in other European countries. The company aims to strengthen its position as the leading provider of over-the-counter drugs and health products, with a focus on innovative and natural solutions, through a combination of organic growth and targeted acquisitions of companies with complementary products and technologies. Karo Pharma ist eines der beliebtesten Unternehmen auf Eulerpool.com.Equity Details
Analyzing Karo Pharma's Equity
Karo Pharma's equity represents the ownership interest in the company, calculated as the difference between total assets and total liabilities. It reflects the residual claim by shareholders on the company’s assets after all debts have been paid. Understanding Karo Pharma's equity is essential for assessing its financial health, stability, and value to shareholders.
Year-to-Year Comparison
Evaluating Karo Pharma's equity over successive years offers insights into the company's growth, profitability, and capital structure. Increasing equity indicates an enhancement in net assets and financial health, while decreasing equity could point to rising debts or operational challenges.
Impact on Investments
Karo Pharma's equity is a crucial element for investors, influencing the company's leverage, risk profile, and return on equity (ROE). Higher equity levels generally suggest lower risk and enhanced financial stability, making the company a potentially attractive investment opportunity.
Interpreting Equity Fluctuations
Fluctuations in Karo Pharma’s equity can arise from various factors, including changes in net income, dividend payments, and issuance or buyback of shares. Investors analyze these shifts to gauge the company's financial performance, operational efficiency, and strategic financial management.
Frequently Asked Questions about Karo Pharma stock
What was the equity of Karo Pharma compared to the previous year?
The equity of Karo Pharma has increased/decreased by 0% decreased compared to the previous year.
What impact does a high equity have on investors of Karo Pharma?
A high equity is advantageous for investors of Karo Pharma as it is an indicator of the company's financial stability and its ability to manage risks and challenges.
What impact does low equity have on investors of Karo Pharma?
A low equity can be a risk for investors of Karo Pharma, as it can put the company in a weaker financial position and impair its ability to manage risks and challenges.
How does an increase in equity of Karo Pharma affect the company?
An increase in equity of Karo Pharma can strengthen the company's financial position and improve its ability to make investments in the future.
How does a reduction in the equity of Karo Pharma affect the company?
A reduction in equity of Karo Pharma can affect the financial situation of the company and lead to a higher dependence on debt capital.
What are some factors that influence the equity of Karo Pharma?
Some factors that can affect the equity of Karo Pharma include profits, dividend payments, capital increases, and acquisitions.
Why is the equity of Karo Pharma so important for investors?
The equity of Karo Pharma is important for investors as it is an indicator of the financial strength of the company and can be an indication of how well the company is able to fulfill its financial obligations.
What strategic measures can Karo Pharma take to change the equity?
To change equity, Karo Pharma can take various measures such as increasing profits, conducting capital increases, reducing expenses, and acquiring companies. It is important for the company to perform a thorough review of its financial situation to determine the best strategic actions to modify its equity.
How much dividend does Karo Pharma pay?
Over the past 12 months, Karo Pharma paid a dividend of 0.27 SEK . This corresponds to a dividend yield of about 0.45 %. For the coming 12 months, Karo Pharma is expected to pay a dividend of 0.4 SEK.
What is the dividend yield of Karo Pharma?
The current dividend yield of Karo Pharma is 0.45 %.
When does Karo Pharma pay dividends?
Karo Pharma pays a quarterly dividend. This is distributed in the months of .
How secure is the dividend of Karo Pharma?
Karo Pharma paid dividends every year for the past 4 years.
What is the dividend of Karo Pharma?
For the upcoming 12 months, dividends amounting to 0.4 SEK are expected. This corresponds to a dividend yield of 0.66 %.
In which sector is Karo Pharma located?
Karo Pharma is assigned to the 'Health' sector.
Wann musste ich die Aktien von Karo Pharma kaufen, um die vorherige Dividende zu erhalten?
To receive the latest dividend of Karo Pharma from 5/11/2018 amounting to 0.3 SEK, you needed to have the stock in your portfolio before the ex-date on 5/4/2018.
When did Karo Pharma pay the last dividend?
The last dividend was paid out on 5/11/2018.
What was the dividend of Karo Pharma in the year 2023?
In the year 2023, Karo Pharma distributed 0 SEK as dividends.
In which currency does Karo Pharma pay out the dividend?
The dividends of Karo Pharma are distributed in SEK.
Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.
Andere Kennzahlen von Karo Pharma
Our stock analysis for Karo Pharma Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Karo Pharma Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.
